Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Pharmacological treatment of growth hormone deficiency (GHD) in adults began in clinical practice more than 20 years ago. Since then, a great volume of experience has been accumulated on its effects on the symptoms and biochemical alterations that characterize this hormonal deficiency. The effects on body composition, muscle mass and strength, exercise capacity, glucose and lipid profile, bone metabolism, and quality of life have been fully demonstrated. The advance of knowledge has also taken place in the biological and molecular aspects of the action of this hormone in patients who have completed longitudinal growth. In recent years, several epidemiological studies have reported interesting information about the long-term effects of GH replacement therapy in regard to the possible induction of neoplasms and the potential development of diabetes. In addition, GH hormone receptor polymorphism could potentially influence GH therapy. Long-acting GH are under development to create a more convenient GH dosing profile, while retaining the excellent safety, efficacy, and tolerability of daily GH. In this article we compile the most recent data of GH replacement therapy in adults, as well as the molecular aspects that may condition a different sensitivity to this treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Retrospective [43,44] and prospective [45] studies have shown that patients with hypopituitarism treated with usual replacement therapy without GH exhibit an increased mortality in comparison with general population, especially concerning CV disease.”
BackgroundSalomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · cited 1×
“Therefore, GH dose requirements are lower in older patients and higher in some transition and young adult patients [20], especially if serum IGF-I are very low [37].”
BackgroundLong-term safety of recombinant human growth hormone in children
Bell, J., Parker, K. L., Swinford, R. D., Hoffman, A. R., Maneatis, T., & Lippe, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0178 · Cited by 301
Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults
Götherström, G., Elbornsson, M., Stibrant-Sunnerhagen, K., Bengtsson, B.-A., Johannsson, G., & Svensson, J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1538 · Cited by 85
Götherström, G., Bengtsson, B.-A., Bosæus, I., Johannsson, G., & Svensson, J. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02317 · Cited by 76 · cited 1×
“This study suggests that adequate estrogen replacement is needed in order to have an optimal response in bone mineral density in GHD women [25].”
BackgroundChild, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1123 · Cited by 58 · cited 1×
“[78] reported the incidence of primary neoplasia in a cohort of 8418 patients treated with GH, as well as in 3668 GH-treated patients with history of pituitary adenoma and 956 GH-treated patients with history of craniopharyngiomas.”
BackgroundQuigley, C. A., Child, C. J., Zimmermann, A. G., Rosenfeld, R. G., Robison, L. L., & Blum, W. F. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00214 · Cited by 33 · cited 1×
“On the contrary, the observational GeNeSIS study, evaluating 9504 GH-treated children followed for at least four years found no increase in risk of mortality compared with children in the general population [85].”
ResultGiavoli, C., Profka, E., Verrua, E., Ronchi, C. L., Ferrante, E., Bergamaschi, S., Sala, E., Malchiodi, E., Lania, A. G., Arosio, M., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2477 · Cited by 25 · cited 1×
“This particular group of patients exhibits a significant deterioration of health-related QoL that is improved by GH replacement [29].”
Background
Cited by
Castoldi, R. C., Ozaki, G. A. T., Garcia, T. A., Giometti, I. C., Koike, T. E., Camargo, R. C. T., dos Santos Pereira, J. D. A., Constantino, C. J. L., Louzada, M. J. Q., Camargo Filho, J. C. S., et al. (2020) · Lasers in Medical Science · doi:10.1007/s10103-019-02821-5 · Cited by 9
Circulating levels of growth hormone in postural orthostatic tachycardia syndrome
Johansson, M., Ricci, F., Schulte, J., Persson, M., Melander, O., Sutton, R., Hamrefors, V., & Fedorowski, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-87983-5 · Cited by 9
Assessment of anterior-posterior spinal curvatures in children suffering from hypopituitarism
Kobylińska, M., Malak, R., Majewska, K., Kędzia, A., & Samborski, W. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0462-4 · Cited by 5
Metadata
- Authors
- Díez, J. J., Sangiao-Alvarellos, S., & Cordido, F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-03-17
- Volume
- 19
- Issue
- 3
- Pages
- 893
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2790182762
- Cited by
- 81
- References
- 11
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks. https://app.cochat.ai/papers/10.3390/ijms19030893
- The paper
- Díez, J. J., Sangiao-Alvarellos, S., & Cordido, F. (2018). Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19030893
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.